Bibliography
- Bergman M. Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 2013.43:504–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23132321
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum 2012;154-71
- Boyle LD, Wilding JPH. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. Expert Opin Emerg Drugs 2013.18:375-91. Available from: www.ncbi.nlm.nih.gov/pubmed/23968378
- Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5:133-41
- Lee H, Han KH, Park HW, et al. Familial renal glucosuria: a clinicogenetic study of 23 additional cases. Pediatr Nephrol 2012;27:1091-5
- Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 2013.304:E117-30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23149623
- Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-15
- Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-18
- Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007.S27-35. Available from: www.ncbi.nlm.nih.gov/pubmed/17653207
- Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013.1-8. Available from: www.ncbi.nlm.nih.gov/pubmed/23412078
- Cada DJ, Ingram KT, Levien TL, Baker DE. Canagliflozin. Hosp Pharm. 2013.48:855-67. Available from: www.ncbi.nlm.nih.gov/pubmed/24493489
- Dietrich E, Powell J, Taylor JR. Canagliflozin: a novel treatment option for type 2 diabetes. Drug Des Devel Ther 2013.7:1399-408. Available from: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3840773&tool=pmcentrez&rendertype=abstract
- Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013;6:453-67
- Stenlöf K, Cefalu WT, Kim K, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013.15:372-82. Available from: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3593184&tool=pmcentrez&rendertype=abstract
- Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013.15:1136-45. Available from: www.ncbi.nlm.nih.gov/pubmed/23782594
- Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8
- Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92. Available from: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3825495&tool=pmcentrez&rendertype=abstract
- Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013.67:1267-82. Available from: www.ncbi.nlm.nih.gov/pubmed/24118688
- Bailey RA, Damaraju CV, Martin SC, et al. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin. Am J Manag Care 2014;20(1):16-24
- Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014. Available from: www.ncbi.nlm.nih.gov/pubmed/24528605
- Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013.36:2508-15. Available from: www.ncbi.nlm.nih.gov/pubmed/23564919
- Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012.14:539-45. Available from: http://doi.wiley.com/10.1111/j.1463-1326.2012.01558.x\⊂npapers2://publication/doi/10.1111/j.1463-1326.2012.01558.x
- Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: A pooled analysis of clinical studies. Curr Med Res Opin 2014.30:1109-19. Available from: www.embase.com/search/results?subaction=viewrecord&from=export&id=L373100744\⊂nhttp://dx.doi.org/10.1185/03007995.2014.890925\⊂nhttp://dd8gh5yx7k.search.serialssolutions.com?sid=EMBASE&issn=14734877&id=doi:10.1185/03007995.2014.890925&atitle=Genital+mycotic+infections+with+canagliflozin,+a+sodium+glucose+co-transporter+2+inhibitor,+in+patients+with+type+2+diabetes+mellitus:+A+pooled+analysis+of+clinical+studies&stitle=Curr.+Med.+Res.+Opin.&title=Current+Medical+Research+and+Opinion&volume=30&
- Janssen Research & Development L. Canagliflozin as an Adjunctive Treatment to Diet and Exercise Alone or Co-administered with Other Antihyperglycemic Agents to Improve Glycemic Control in Adults with Type 2 Diabetes Mellitus [Internet]. Endocrinologic and Metabolic Drugs Advisory Committee. 2013. Available from: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm334551.pdf [Cited 22 April 2014]
- Scheen AJ. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet 2014.53(4):295-304. Available from: www.ncbi.nlm.nih.gov/pubmed/24420910
- Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J 2013.166:217-223.e11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23895803
- Yale J, Bakris G, Cariou B. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013.463-73. Available from: http://onlinelibrary.wiley.com/doi/10.1111/dom.12090/full
- Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013;41(2):72-84
- Gross JL, Schernthaner G, Fu M, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulfonylurea [abstract]. In: Program and abstracts from the 72nd Scientific Sessions of the American Diabetes Association; Philadelphia, PA; 2012. Abstract 50-LB